Compare Hims and Hers Health Inc (HIMS) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Omnicom Group Inc. — how do they compare? Hims and Hers Health Inc trades at $29.29 (market cap $6.55B), while Omnicom Group Inc. trades at $76.62 (market cap $20.97B). The key difference: Omnicom Group Inc. is far larger — about 3.2× Hims and Hers Health Inc's market cap, and Omnicom Group Inc. pays a 4.19% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Omnicom Group Inc. for 63 Days on average.
| HIMS | OMC | |
|---|---|---|
Market Cap | $6.55B | $20.97B |
Volume | 14,842,814 | 2,092,899 |
Sector | Health | Media |
52-Week High | $62.76 | $88.94 |
52-Week Low | $14.52 | $67.27 |
Typical Hold Time | 21 Days | 63 Days |
Enterprise Value | $7.25B | $29.05B |
Dividend Yield | — | 4.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.
The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.
Omnicom Group (OMC) trades at $74.87, down 0.31% on the day, with a bearish technical outlook. The stock shows mixed fundamentals with strong revenue growth to $17.27B in 2025 but negative net income of -$54.5M. Recent business developments include significant new billings of $3.3B in H1 2026 and leadership recognition in Gartner reports. Analyst consensus is mixed with 32% buy ratings but a $100.50 price target suggesting 34% upside potential.
OMC presents a value opportunity with attractive valuation metrics (P/S 0.86) and dividend yield, though recent earnings misses and high P/E ratio of 206.62 raise concerns. Key risks include advertising market volatility and debt levels, while catalysts include AI integration and post-merger synergies from the Interpublic acquisition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
